These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8618603)

  • 21. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
    Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
    Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
    Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
    N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis.
    Kappel PJ; Charonis AC; Holland GN; Narayanan R; Kulkarni AD; Yu F; Boyer DS; Engstrom RE; Kuppermann BD;
    Ophthalmology; 2006 Apr; 113(4):683.e1-8. PubMed ID: 16581428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The prognostic value of cytomegalovirus antigenemia and viremia for the development of cytomegalovirus disease and the survival of AIDS patients].
    Cartón JA; Maradona JA; de Oña M; Asensi V; Melón S; García-Alcalde ML; Rodríguez-Junquera M; Moreno-Torrico A; de Zárraga M
    Med Clin (Barc); 1999 Sep; 113(6):205-9. PubMed ID: 10472608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group.
    Parente F; Bianchi Porro G
    Am J Gastroenterol; 1998 Mar; 93(3):317-22. PubMed ID: 9517631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis.
    Martin BK; Ricks MO; Forman MS; Jabs DA;
    Clin Infect Dis; 2007 Apr; 44(7):1001-8. PubMed ID: 17342657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.
    Brosgart CL; Louis TA; Hillman DW; Craig CP; Alston B; Fisher E; Abrams DI; Luskin-Hawk RL; Sampson JH; Ward DJ; Thompson MA; Torres RA
    AIDS; 1998 Feb; 12(3):269-77. PubMed ID: 9517989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMV news.
    Posit Aware; 1996; 7(1):5-6. PubMed ID: 11363124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral ganciclovir.
    Schouten JT
    STEP Perspect; 1995; 7(3):1, 11. PubMed ID: 11362979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
    Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV
    J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognosis of CMV retinitis among patients with AIDS in Serbia.
    Dujić M; Jevtović Dj; Salemović D; Ranin J; Brmbolić B; Djurković-Djaković O
    Biomed Pharmacother; 2008 Sep; 62(7):443-7. PubMed ID: 18243635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation.
    Goodrich JM; Mori M; Gleaves CA; Du Mond C; Cays M; Ebeling DF; Buhles WC; DeArmond B; Meyers JD
    N Engl J Med; 1991 Dec; 325(23):1601-7. PubMed ID: 1658652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
    Powderly WG; Finkelstein D; Feinberg J; Frame P; He W; van der Horst C; Koletar SL; Eyster ME; Carey J; Waskin H
    N Engl J Med; 1995 Mar; 332(11):700-5. PubMed ID: 7854376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consequences for the management of cytomegalovirus.
    Katlama C
    AIDS; 1996 Nov; 10 Suppl 1():S43-6. PubMed ID: 8970676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing.
    Rose DN; Sacks HS
    AIDS; 1997 Jun; 11(7):883-7. PubMed ID: 9189213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group.
    Arch Ophthalmol; 1997 Dec; 115(12):1528-36. PubMed ID: 9400786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.